Gabinet Okulistyczny Prof Edward WylegalaĬentrum Diagnostyki i Mikrochirurgii Oka LENSĮmanuelli Research and Development Center LLCįakultna nemocnica s poliklinikou F.D. The Woodlands, Texas, United States, 77384Įast Melbourne, Victoria, Australia, 3002 The Woodlands, Texas, United States, 77384-4167
Germantown, Tennessee, United States, 38138 Southeastern Retina Associates ChattanoogaĬhattanooga, Tennessee, United States, 37421 Ladson, South Carolina, United States, 29456 Oceanside, New York, United States, 11572Ĭharlotte Eye Ear Nose and Throat AssociatesĬharlotte, North Carolina, United States, 28210 Southaven, Mississippi, United States, 38671īloomfield, New Jersey, United States, 07003Īlbuquerque, New Mexico, United States, 87109 University of Michigan, Kellogg Eye CenterĪnn Arbor, Michigan, United States, 48105 Hagerstown, Maryland, United States, 21740 Oak Forest, Illinois, United States, 60452
#Retina associates tucson Pc
University Retina and Macula Associates, PC Saint Petersburg, Florida, United States, 33711 Waterford, Connecticut, United States, 06385ĭeerfield Beach, Florida, United States, 33064 Retina Consultants of Southern Colorado PCĬolorado Springs, Colorado, United States, 80909 Torrance, California, United States, 90502 Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center Glendale, California, United States, 91204 Use of systemic medications known to be toxic to the lens, retina or optic nerve (e.g., deferoxamine, chloroquine/hydroxychloroquine, tamoxifen, phenothiazines and ethambutol) used during the 6-month period prior to screening or likely need to be usedĪrcadia, California, United States, 91006.Known hypersensitivity to any of the excipients of the drug used, fluorescein dye or dilating eye drops.History of or currently active other diseases, metabolic dysfunction, physical examination finding, malignancies not considered cured, or clinical laboratory findings giving reasonable suspicion of a condition that contraindicated the use of the investigational medicinal drug or that might affect interpretation of the results of the study or renders the patient at high risk for treatment complications in the opinion of the investigator.Any major illness or major surgical procedure within one month before screening.History of concurrent cardio-vascular disease not considered well controlled by the Investigator.Hemoglobin A1c (HbA1c) 180mmHg and/or diastolic >100 mmHg while patient at rest).Diagnosis of diabetes mellitus (DM) type 1 or type 2.Clear ocular media and adequate pupillary dilation to allow acquisition of good quality retinal images.
BCVA score at screening of at least 70 letters in study eyes without DME and at least 75 letters in case DME is present.Patients are eligible with and without DME in either eye.Treatment naïve with moderately severe to severe NPDR defined as ETDRS DRSS 47 or 53.Male and female patients of at least 18 years of age.Able and willing to provide written informed consent and to comply with the study protocol according to International Conference of Harmonization (ICH) and local regulations.Why Should I Register and Submit Results?.
0 kommentar(er)
